MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
798.58%
Quick Ratio
781.47%
Cash Ratio
721.57%
Debt to Asset Ratio
13.17%
Unit: Dollar
Assets Breakdown
    • Cash and cash equivalents
    • Prepaid expenses and other curre...
    • Inventories
    • Deferred financing costs
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accounts payable
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash
-
-
1,003,904
1,948,271
Cash and cash equivalents
12,167,136
5,857,024
-
-
Prepaid expenses and other current assets
1,009,958
890,149
55,102
419,421
Inventories
288,450
369,974
253,160
35,437
Total current assets
13,465,544
7,117,147
1,312,166
2,403,129
Deferred financing costs
75,000
-
-
-
Total assets
13,540,544
7,117,147
1,312,166
2,403,129
Due to affiliate-Affiliates
-
353,679
353,679
353,679
Due to affiliate
0
-
-
-
Promissory note fee related party
0
1,000,000
1,000,000
1,000,000
Loan and transfer notes payable related party
0
499,214
499,214
499,214
Subscription agreement loans
0
-
1,500,000
1,500,000
Convertible notes
0
-
1,290,476
4,739,965
Notes payable related party
0
-
885,564
885,564
Derivative liability
0
-
40,954
3,554,265
Accounts payable
972,108
857,925
1,014,377
1,060,889
Accrued expenses
714,088
441,614
1,008,569
266,930
Total current liabilities
1,686,196
3,152,432
7,592,833
13,860,506
Forward purchase agreement liability
96,527
96,252
95,662
9,901
Total liabilities
1,782,723
3,248,684
7,688,495
13,870,407
Series a convertible preferred stock, 30,000 and 0 shares as designated, respectively, 0.0001 par value 17,050 and 0 shares issued or outstanding, respectively
2
1
-
-
Common stock 0.0001 par value 490,000,000 shares authorized 1,295,234 and 117,780 issued and outstanding, respectively
129
17
353
4,953
Additional paid-in capital
43,506,805
34,349,418
20,881,399
11,078,116
Accumulated deficit
-31,749,115
-30,480,973
-27,258,081
-22,550,347
Total stockholders equity (deficit)
11,757,821
3,868,463
-6,376,329
-11,467,278
Total liabilities and stockholders equity (deficit)
13,540,544
7,117,147
1,312,166
2,403,129
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$12,167,136 Prepaid expenses andother current assets$1,009,958 (28.95%↑ Y/Y)Inventories$288,450 Total current assets$13,465,544 (1260.95%↑ Y/Y)Deferred financing costs$75,000 Total assets$13,540,544 (1268.53%↑ Y/Y)Total liabilities andstockholders equity...$13,540,544 (1268.53%↑ Y/Y)Total stockholdersequity (deficit)$11,757,821 (222.26%↑ Y/Y)Total liabilities$1,782,723 (-83.19%↓ Y/Y)Accumulated deficit-$31,749,115 (-53.38%↓ Y/Y)Additional paid-in capital$43,506,805 (292.73%↑ Y/Y)Total currentliabilities$1,686,196 (-84.03%↓ Y/Y)Forward purchaseagreement liability$96,527 (95.85%↑ Y/Y)Common stock 0.0001 parvalue 490,000,000...$129 (-97.40%↓ Y/Y)Series a convertiblepreferred stock, 30,000...$2 Accounts payable$972,108 (-28.08%↓ Y/Y)Accrued expenses$714,088 (88.82%↑ Y/Y)

Aspire Biopharma Holdings, Inc. (ASBPW)

Aspire Biopharma Holdings, Inc. (ASBPW)